Glioma News and Research RSS Feed - Glioma News and Research

Glioma is a cancer of the brain that begins in glial cells (cells that surround and support nerve cells).
BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed two new method of treatment patent applications with the United States Patent and Trademark Office to cover methods of treating brain tumors as well as cancers expressing a mutant form of RAS protein through administration of the Company’s lead compound, Plinabulin. [More]
Experimental drug that attacks brain tumor cells passes early tests

Experimental drug that attacks brain tumor cells passes early tests

An experimental drug that attacks brain tumor tissue by crippling the cells' energy source called the mitochondria has passed early tests in animal models and human tissue cultures, say Houston Methodist scientists. [More]
EHT expert paper raises important and unanswered questions about safety of wearable tech

EHT expert paper raises important and unanswered questions about safety of wearable tech

Wearable technology is raising health concerns worldwide. A recent New York Times article by Nick Bilton is raising important and unanswered questions about the safety of wearable tech, according to the non-profit research group, Environmental Health Trust. [More]
Slow-growing tumors have treatment-resistant stem cells, shows study

Slow-growing tumors have treatment-resistant stem cells, shows study

Scientists are eager to make use of stem cells' extraordinary power to transform into nearly any kind of cell, but that ability also is cause for concern in cancer treatment. [More]
Brain tumor experts launch revolutionary fast-track approach to cancer research

Brain tumor experts launch revolutionary fast-track approach to cancer research

Brain tumor experts at Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center have launched a revolutionary fast-track approach to cancer research, giving new hope to brain cancer patients. [More]
Chemotherapy, radiation therapy combination improves outcomes for people with low-grade brain cancer

Chemotherapy, radiation therapy combination improves outcomes for people with low-grade brain cancer

New clinical-trial findings provide further evidence that combining chemotherapy with radiation therapy is the best treatment for people with a low-grade form of brain cancer. The findings come from a phase II study co-led by a researcher at Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and researchers at the University of Maryland and at London Regional Cancer Program in Ontario, Canada. [More]
Novogen's TRXE-009 therapy shows promise against brain cancer

Novogen's TRXE-009 therapy shows promise against brain cancer

Australian/US biotechnology company, Novogen Limited, today announces that it has confirmed that one of its lead candidate products, TRXE-009, is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer. [More]
Novel drug mechanism shows promise against glioma cells

Novel drug mechanism shows promise against glioma cells

Researchers at UC Davis have developed and characterized a molecule that interferes with the internal regulation of cancer cells, causing them to self-destruct. This novel mechanism was found to be effective against glioma cells - responsible for a usually fatal type of brain cancer - and could be applicable to other highly aggressive cancers. [More]
MD Anderson scientists show why some brain cancer patients develop resistance to treatments

MD Anderson scientists show why some brain cancer patients develop resistance to treatments

Scientists at The University of Texas MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including radiation and the chemotherapy agent temozolomide. [More]
New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

There are no effective available treatments for sufferers of Glioblastoma multiforme (GBM), the most aggressive and devastating form of brain tumor. The disease, always fatal, has a survival rate of only 6-18 months. [More]
Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Cancer vaccines are designed to turn the body's own immune system specifically against tumor cells. Particularly promising are vaccines that are directed against so-called neoantigens: These are proteins that have undergone a genetic mutation in tumor cells and, therefore, differ from their counterparts in healthy cells. [More]
Drug similar to Gleevec may help tame some brain cancers

Drug similar to Gleevec may help tame some brain cancers

The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. The drug was specifically designed to target an abnormal molecule--a fusion of two normal cell proteins--that fueled a tumor's growth. [More]
Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA") for REOLYSIN® for the treatment of high grade gliomas (HGG) in pediatric patients. [More]
Johns Hopkins researchers successfully deliver new nanoparticle gene therapy to treat glioma in rats

Johns Hopkins researchers successfully deliver new nanoparticle gene therapy to treat glioma in rats

Despite improvements in the past few decades with surgery, chemotherapy and radiation therapy, a predictably curative treatment for glioma does not yet exist. New insights into specific gene mutations that arise in this often deadly form of brain cancer have pointed to the potential of gene therapy, but it's very difficult to effectively deliver toxic or missing genes to cancer cells in the brain. [More]
Two new fluorescent dyes may help localize, resect brain tumors

Two new fluorescent dyes may help localize, resect brain tumors

Two new fluorescent dyes attracted to cancer cells may help neurosurgeons more accurately localize and completely resect brain tumors, suggests a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. [More]
Novel technique could help identify cancerous tissue during brain tumor surgery

Novel technique could help identify cancerous tissue during brain tumor surgery

A novel radioguided surgery technique could quickly and effectively identify residual cancer cells during brain tumor surgery, with low radiation exposure for both patients and surgeons. The study, featured in the January 2015 issue of the Journal of Nuclear Medicine, reports that Y-90 DOTATOC, a beta-minus-emitting tracer, can effectively delineate the margins of meningiomas and high-grade gliomas. [More]
Taking hormonal contraceptives for five years doubles brain tumour risk

Taking hormonal contraceptives for five years doubles brain tumour risk

Taking a hormonal contraceptive for at least five years is associated with a possible increase in a young woman's risk of developing a rare tumour, glioma of the brain. This project focussed on women aged 15 -49 years and the findings are published in the British Journal of Clinical Pharmacology. [More]
Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Kinex Pharmaceuticals doses first patient with KX2-361 in ‘A Phase 1’ clinical trial

Kinex Pharmaceuticals announced today that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute. [More]
Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma. [More]
Research finding could lead to new therapies for malignant glioma

Research finding could lead to new therapies for malignant glioma

Targeted therapies are a growing and groundbreaking field in cancer care in which drugs or other substances are designed to interfere with genes or molecules that control the growth and survival of cancer cells. Now, scientists at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) have identified a novel interaction between a microRNA and a gene that could lead to new therapies for the most common and deadly form of brain tumor, malignant glioma. [More]
Advertisement
Advertisement